These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 13803816)

  • 21. HISTOLOGICAL AND HISTOCHEMICAL DATA ON THE PROCESS OF REGRESSION OF EXPERIMENTAL TUMOURS INDUCED BY ALKYLATING AGENTS.
    PRESNOV MA
    Acta Unio Int Contra Cancrum; 1964; 20():126-30. PubMed ID: 14151866
    [No Abstract]   [Full Text] [Related]  

  • 22. AZASERINE AND THIOPURINES. I. INHIBITION OF S-180 MOUSE TUMOR AND ANTIBODY SYNTHESIS.
    HANSEN HJ; VANDEVOORDE JP; BENNETT KJ; GILES WG; NADLER SB
    J Lab Clin Med; 1964 May; 63():801-18. PubMed ID: 14158063
    [No Abstract]   [Full Text] [Related]  

  • 23. [COMPARATIVE STUDY OF THE SPECTRUM OF ACTION OF ANTINEOPLASTIC PREPARATIONS OF THE ALKYLATING AGENT GROUP ON TRANSPLANTABLE TUMORS IN MICE].
    BOKAEVA SS
    Biull Eksp Biol Med; 1965 Mar; 59():86-8. PubMed ID: 14310877
    [No Abstract]   [Full Text] [Related]  

  • 24. [Antitumoral action of triethylene melamine-isonicotinic acid hydrazide association on Galliera sarcoma of the rat].
    BALDINI L; BRAMBILLA G
    Boll Soc Ital Biol Sper; 1959 Sep; 35():1171-5. PubMed ID: 13796135
    [No Abstract]   [Full Text] [Related]  

  • 25. [Inhibitory action of isonicotinic acid hydrazide on the development of Galliera sarcoma in the rat].
    BRAMBILLA G; BALDINI L
    Boll Soc Ital Biol Sper; 1959 Sep; 35():1169-71. PubMed ID: 13803815
    [No Abstract]   [Full Text] [Related]  

  • 26. [Experimental neoplasms induced by alkylating cytostatics and alkylating antibiotics].
    Roth J
    Hippokrates; 1971 Jun; 42(2):231-3. PubMed ID: 5566032
    [No Abstract]   [Full Text] [Related]  

  • 27. Increase of glycogen and oligosaccharide contents in ascites tumor cells under the influence of alkylating agents.
    Tashiro T; Sakurai Y
    Gan; 1969 Aug; 60(4):465-8. PubMed ID: 4310237
    [No Abstract]   [Full Text] [Related]  

  • 28. [Action of 6-mercaptopurine and of 8-azaguanine on Galliera sarcoma in the rat].
    BRAMBILLA G; BALDINI L
    Boll Soc Ital Biol Sper; 1960 Jun; 36():586-7. PubMed ID: 13803813
    [No Abstract]   [Full Text] [Related]  

  • 29. [Carcinogenic effects of antineoplastic and immunosuppressive agents].
    Brock N; Schneider H
    Arzneimittelforschung; 1971 Sep; 21(9):1406-10. PubMed ID: 5171799
    [No Abstract]   [Full Text] [Related]  

  • 30. [CYTOSTATIC THERAPY WITH ALKYLATING AGENTS FOR MALIGNANT TUMORS].
    SCHUMACHER K; LANGE J
    Dtsch Med J; 1964 Nov; 15():761-5. PubMed ID: 14329920
    [No Abstract]   [Full Text] [Related]  

  • 31. Experimental approaches to evaluating the activities of alkylating agents.
    SCHMIDT LH
    Cancer Chemother Rep; 1962 Feb; 16():25-8. PubMed ID: 13908772
    [No Abstract]   [Full Text] [Related]  

  • 32. [Searching for antineoplastic agents. II. Effect of 38 synthetic compounds from the group III-X on the growth of Crocker's sarcoma in mice. Biological section].
    RADZIKOWSKI C; LEDOCHOWSKI Z; LEDOCHOWSKI A; RUPRECHT M; HRABOWSKA M
    Patol Pol; 1962; 13():39-58. PubMed ID: 14489797
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of compounds on a spectrum of rat tumors.
    Sugiura K; Schmid FA; Schmid MM; Brown GF
    Cancer Chemother Rep 2; 1972 Nov; 3(1):231-308. PubMed ID: 4350013
    [No Abstract]   [Full Text] [Related]  

  • 34. [Effect of bone marrow homotransplantation on the toxicity and antineoplastic property of some alkylating agents].
    Veksler IG; Shevchenko VN
    Vopr Onkol; 1965; 11(7):71-6. PubMed ID: 4956684
    [No Abstract]   [Full Text] [Related]  

  • 35. [On the evaluation of the persistence of the antimitotic activity of alkylating agents in solution].
    DEYSSON G; TRUHAUT R
    C R Hebd Seances Acad Sci; 1962 Jun; 254():4521-3. PubMed ID: 13885943
    [No Abstract]   [Full Text] [Related]  

  • 36. Cyclophosphamide. A preliminary study of a new alkylating agent.
    FOYE LV; CHAPMAN CG; WILLETT FM; ADAMS WS
    Cancer Chemother Rep; 1960 Feb; 6():39-40. PubMed ID: 13824276
    [No Abstract]   [Full Text] [Related]  

  • 37. THE USE OF THE DRUGS AB 103 AND AB 132 IN THE COMBINED TREATMENT OF TUMOURS OF THE CERVICAL AND PULMONARY REGIONS.
    MECHL Z; KOLAR V; KONECNY M
    Neoplasma; 1964; 11():491-8. PubMed ID: 14220338
    [No Abstract]   [Full Text] [Related]  

  • 38. Differential sensitivity of mouse spermatogenesis to alkylating agents.
    MOUTSCHEN J
    Genetics; 1961 Mar; 46(3):291-9. PubMed ID: 13773334
    [No Abstract]   [Full Text] [Related]  

  • 39. [CHEMOTHERAPY OF MALIGNANT NEOPLASMS].
    KROESE WF; BREUR K
    Ned Tijdschr Geneeskd; 1964 Dec; 108():2357-62. PubMed ID: 14260300
    [No Abstract]   [Full Text] [Related]  

  • 40. [Method for the primary selection of active antitumor alkylating preparations in vitro and in vivo].
    Montsevichiute-Eringene EV
    Vopr Onkol; 1975; 21(10):73-7. PubMed ID: 1189354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.